Paweł Sobczuk (Pawel Sobczuk)

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 19

Top Topics

Clinical Practice

Renal Cell Carcinoma

Top Venues

Journal of cancer research and clinical oncology

Expert opinion on pharmacotherapy

Cancer immunology, immunotherapy : CII

This page only lists publications with an associated author ORCID identifier.

Publications

Paweł Sobczuk, Michał Cholewiński, Piotr Lukasz Rutkowski
Recent advances in tyrosine kinase inhibitors VEGFR 1-3 for the treatment of advanced metastatic melanoma. Expert opinion on pharmacotherapy (2024)
Paweł Sobczuk, Michał Cholewiński, Piotr Lukasz Rutkowski
Recent advances in tyrosine kinase inhibitors VEGFR 1-3 for the treatment of advanced metastatic melanoma. Expert opinion on pharmacotherapy (2024)
Paweł Sobczuk, Michał Cholewiński, Piotr Lukasz Rutkowski
Recent advances in tyrosine kinase inhibitors VEGFR 1-3 for the treatment of advanced metastatic melanoma. Expert opinion on pharmacotherapy 25 (5) (2024)
Natalia Banaszek, Dominika Kurpiewska, Katarzyna Kozak, Piotr Lukasz Rutkowski, Paweł Sobczuk
Hedgehog pathway in sarcoma: from preclinical mechanism to clinical application. Journal of cancer research and clinical oncology (2023)
Wiktoria Jędrys, Aleksandra Leśniak, Aneta Borkowska, Piotr Lukasz Rutkowski, Paweł Sobczuk
Brain metastases of sarcoma: a rare phenomenon in rare tumours. Journal of cancer research and clinical oncology (2023)
Joanna Placzke, Magdalena Rosinska, Paweł Sobczuk, Marcin Ziętek, Natasza Kempa-Kamińska, Bozena Cybulska-Stopa, Grażyna Kamińska-Winciorek, Wiesław Bal, Jacek Mackiewicz, Łukasz Galus, Manuela Las-Jankowska, Michał Jankowski, Robert Dziura, Kamil Drucis, Aneta Borkowska, Tomasz Świtaj, Paweł Rogala, Katarzyna Kozak, Anna Klimczak, Paulina Jagodzińska-Mucha, Anna Szumera-Ciećkiewicz, Hanna Kosela-Paterczyk, Piotr Rutkowski
Modern Approach to Melanoma Adjuvant Treatment with Anti-PD1 Immune Check Point Inhibitors or BRAF/MEK Targeted Therapy: Multicenter Real-World Report. Cancers 15 (17) (2023)
Paweł Sobczuk, Huber Bątruk, Paulina Wójcik, Krzysztof Iwaniak, Katarzyna Kozak, Piotr Lukasz Rutkowski
In search of effective therapies: the current landscape of phase II trials in patients with advanced soft tissue sarcoma. Journal of cancer research and clinical oncology (2022)
Anna Małgorzata Czarnecka, Paweł Sobczuk, Paweł Rogala, Tomasz Świtaj, Joanna Placzke, Katarzyna Kozak, Anna Mariuk-Jarema, Mateusz Jacek Spałek, Monika Dudzisz-Śledź, Pawel P Teterycz, Aneta Borkowska, Piotr Lukasz Rutkowski
Efficacy of immunotherapy beyond RECIST progression in advanced melanoma: a real-world evidence. Cancer immunology, immunotherapy : CII 71 (8) (2022)
Anna Dawidowska, Paulina Jagodzinska-Mucha, Hanna Kosela-Paterczyk, Sylwia Jaczewska, Paweł Sobczuk, Monika Chelstowska, Maria Małgorzata Kowalska, Honorata Badziak-Sterczewska, Jan Poleszhuk, Piotr Lukasz Rutkowski, Iwona Lugowska
Immune-Related Thyroid Adverse Events Predict Response to PD-1 Blockade in Patients with Melanoma. Cancers 14 (5) (2022)
Monika Dudzisz-Sledz, Paweł Sobczuk, Katarzyna Kozak, Tomasz Switaj, Hanna Kosela-Paterczyk, Anna Małgorzata Czarnecka, Slawomir Falkowski, Paweł Rogala, Tadeusz Morysinski, Mateusz Jacek Spałek, Marcin Zdzienicki, Tomasz Goryn, Marcin Zietek, Bozena Cybulska-Stopa, Stanisław Klek, Grażyna Kamińska-Winciorek, Barbara Ziolkowska, Anna Szumera-Cieckiewicz, Piotr Lukasz Rutkowski
Treatment of Locally Advanced Merkel Cell Carcinoma-A Multi-Center Study. Cancers 14 (2) (2022)
Paweł Sobczuk, Jacek Dziedziak, Natalia Bierezowicz, Marta Kiziak, Zuzanna Znajdek, Liana Puchalska, Dagmara M Mirowska-Guzel, Agnieszka Cudnoch-Jedrzejewska
Are medical students interested in research? - students' attitudes towards research. Annals of medicine 54 (1) (2022)
Paweł Sobczuk, Katarzyna Kozak, Sylwia Kopeć, Paweł Rogala, Tomasz Świtaj, Hanna Kosela-Paterczyk, Aleksandra Gos, Andrzej Tysarowski, Piotr Lukasz Rutkowski
The Use of ctDNA for BRAF Mutation Testing in Routine Clinical Practice in Patients with Advanced Melanoma. Cancers 14 (3) (2022)
Łukasz Mielczarek, Anna Brodziak, Paweł Sobczuk, Maciej Kawecki, Agnieszka Cudnoch-Jedrzejewska, Anna Małgorzata Czarnecka
Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function. Cancer chemotherapy and pharmacology 87 (6) (2021)
Anna Małgorzata Czarnecka, Paweł Sobczuk, Michal Kostrzanowski, Mateusz Jacek Spałek, Marzanna Chojnacka, Anna Szumera-Cieckiewicz, Piotr Lukasz Rutkowski
Epithelioid Sarcoma-From Genetics to Clinical Practice. Cancers 12 (8) (2020)
Anna Małgorzata Czarnecka, Kamil Jozef Synoradzki, Wiktoria Firlej, Ewa Bartnik, Paweł Sobczuk, Michał Fiedorowicz, Paweł Grieb, Piotr Lukasz Rutkowski
Molecular Biology of Osteosarcoma. Cancers 12 (8) (2020)
Paweł Sobczuk, Michał Łomiak, Agnieszka Cudnoch-Jędrzejewska
Dopamine D1 Receptor in Cancer. Cancers 12 (11) (2020)
Paweł Sobczuk, Magdalena Czerwińska, Marcin Kleibert, Agnieszka Cudnoch-Jedrzejewska
Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system-from molecular mechanisms to therapeutic applications. Heart failure reviews (2020)
Anna Małgorzata Czarnecka, Anna Brodziak, Paweł Sobczuk, Cezary Dendek, Dominika Labochka, Jan Korniluk, Ewa Bartnik, Cezary Szczylik
Metastatic Tumor Burden and Loci as Predictors of First Line Sunitinib Treatment Efficacy in Patients with Renal Cell Carcinoma. Scientific reports 9 (1) (2019)
Anna Brodziak, Paweł Sobczuk, Ewa Bartnik, Michał Fiedorowicz, Camillo Porta, Cezary Szczylik, Anna Małgorzata Czarnecka
Drug resistance in papillary RCC: from putative mechanisms to clinical practicalities. Nature reviews. Urology 16 (11) (2019)